Orphan Medical Xyrem
Executive Summary
Sodium oxybate for treatment of narcolepsy and reduction of cataplexy will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 15. Risk management will be the main focus of the committee's deliberations, FDA said. The NDA, filed Oct. 10, 2000, has received priority review status (1"The Pink Sheet" Nov. 29, 1999, p. 11)